Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2001

View Archived Issues

The Inactine system successful in inactivating the virus that causes foot-and-mouth disease

First patients enrolled in paclitaxel-eluting coronary stent trial

Collaboration to develop fully human monoclonal antibodies announced

Use of SSRIs may reduce risk of myocardial infarction in smokers

Trisenox one step closer to launch in Europe

Gleevec submitted for FDA review in gastrointestinal tumors

Two international studies of OSI-774 commence in NSCLC and pancreatic cancer

EADV news: alefacept provides sustained remission without rebound in psoriasis

AtheroGenics completes first part of phase I trial for its novel RA treatment

AltaRex reviews novel technology and OvaRex data at Engineered Antibodies conference

Topical DNA repair enzyme-containing formulation prevents skin cancer

FDA grants expedited approval for Protonix I.V. in Zollinger-Ellison syndrome Rx

SQN-400, a new photosensitizer, evaluated in patients with liver metatases from colorectal cancer

Orally bioavailable calcitonin conjugates induce osteoclast retraction

Clinical trials of Remicade for congestive heart failure put on hold

Aptheal receives approval in U.K. for treatment of aphthous ulcers

Companies form distribution agreement for new dermis allograft to treat incontinence

ASBMR highlights: promising oral bone anabolic PTH analogue developed at Unigene

Zometa will receive priority review for treatment of bone metastases

Tipifarnib-based antitumor combinations extensively patented by Janssen

Several clinical studies evaluate metformin in PCOS

Three related series of anorectic agents described by Aventis

Sankyo presents new inhibitors of macrophage activity

Dainippon describes preparation, use and compositions for new substituted pyrimidines

Condensed thiazolamines from Novartis act as antagonists at the Y5 receptor

Inhibitors of proinflammatory proteins under study at GSK

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...